The type 4 phosphodiesterase inhibitors rolipram and YM976 facilitate recall of the weak version of the passive avoidance task in the day-old chick

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 2, 2009, Pages 224-230

  Crowe, Simon F ^a   Neath, Joanna ^a   Hale, Matthew W ^a,b  

^a Technology and Engineering   (Australia)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chick; Memory; Passive avoidance; Phosphodiesterase 4; Rolipram; YM976

Indexed keywords

4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTHRANILIC ACID METHYL ESTER; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHICK; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; MEMORY CONSOLIDATION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RECALL;

ANIMALS; AVOIDANCE LEARNING; CHICKENS; MEMORY; MENTAL RECALL; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; PYRIMIDINONES; ROLIPRAM;

EID: 59649125600     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.11.014     Document Type: Article

References (47)

1. Aoki M., Fukunaga M., Kitagawa M., Hayashi K., Morokata T., Ishikawa G., et al. Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice and ferrets. J Pharmacol Exp Ther 295 3 (2000) 1149-1155
2. Aoki M., Kobayashi M., Ishikawa G., Saita Y., Terai Y., Takayama K., et al. Novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7 diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther 297 (2000) 165-173
3. Aoki M., Fukunaga M., Kitagawa M., Sugimoto T., Hirano Y., Kobayashi M., et al. Studies on mechanism of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 298 3 (2001) 1142-1149
4. Ardenghi P., Barros D., Izquierdo L.A., Bevilaqua L., Schroder N., Quevedo J., et al. Late and prolonged post-training memory modulation in entorhinal and parietal cortex by drugs acting on the cAMP/protein kinase A signaling pathway. Behav Pharmacol 8 (1997) 745-754
5. Barad M., Bourtchouladze R., Winder D.G., Golan H., and Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. P Natl Acad Sci USA 95 25 (1998) 15020-15025
6. Blair H.T., Schafe G.E., Bauer E.P., Rodrigues S.M., and LeDoux J.E. Synaptic plasticity in the lateral amygdala: A cellular hypothesis of fear conditioning. Learn Mem 8 (2001) 229-242
7. Blokland A., Schreiber R., and Prickaerts J. Improving memory: a role for phosphodiesterases. Curr Pharm Design 12 20 (2006) 2511-2523
8. Bobon D., Breulet M., Gerard-Vandenhove M.A., Gurot-Goffioul F., Plomteux G., Sastre-y-Hernandez M., et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action?. Eur Arch Psy Clin N 238 (1988) 2-6
9. Brown DF. 1987. The Role of Adenosine 3':5′-cyclic Monophosphate (cAMP) in Memory Formation: A Behavioural, Pharmacological and Biochemical Study. PhD Thesis, La Trobe University, Melbourne, Australia.
10. Bureau Y., Handa M., Zhu Y., Laliberte F., Moore C.S., Liu S., et al. Neuroanatomical and pharmacological assessment of Fos expression induced in the rat brain by the phosphodiesterase-4 inhibitor 6-(4-pyridylmethyl)-8-(3-nitrophenyl) quinoline. Neuropharmacology 51 5 (2006) 974-985
11. Cherry J.A., and Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement and affect. J Comp Neurol 407 (1999) 287-301
12. Crowe S.F., and Hale M.W. Carryover effects associated with the single trial passive avoidance learning task in the young chick. Neurobiol Learn Mem 78 (2002) 321-331
13. Crowe S.F., Ng K.T., and Gibbs M.E. Memory formation processes in weakly reinforced learning. Pharmacol Biochem Beh 33 (1989) 881-887
14. Crowe S.F., Ng K.T., and Gibbs M.E. Memory consolidation of weak training experiences by hormonal treatments. Pharmacol Biochem Beh 37 (1990) 729-734
15. Davis H.P., and Squire L.R. Protein synthesis and memory: a review. Psychol Bull 96 3 (1984) 518-559
16. De Vaus J.E., Gibbs M.E., and Ng K.T. Effects of social isolation on memory formation. Behav Neural Biol 29 4 (1980) 473-480
17. Dyke H.J., and Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Inv Drug 11 1 (2002) 1-13
18. Eckmann F., Fichte K., Meya U., and Sastre-y-Hernandez M. Rolipram in major depression: result of a double blind comparative study with amitriptyline. Curr Ther Res Clin E 43 (1988) 291-295
19. Egawa T., Mishima K., Matsumoto Y., Iwasaki K., Iwasaki K., and Fujiwara M. Rolipram and its optimal isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 75 (1997) 275-281
20. Gibbs M.E., and Ng K.T. Psychobiology of memory: towards a model of memory formation. Biobehav Rev 1 (1977) 113-136
21. Greengard P., Allen P.B., and Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23 3 (1999) 435-447
22. Guzowski J., and McGaugh J.L. Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training. Proc Natl Acad Sci USA 94 (1997) 2693-2698
23. Hale M.W., and Crowe S.F. Facilitation and disruption of memory for the passive avoidance task in the day-old chick using dopamine D1 receptor compounds. Behav Pharmacol 14 5 (2003) 525-532
24. Harada N., Nishiyama S., Ohba H., Sato K., Kakiuchi T., and Tsukuda H. Age differences in phosphodiesterase type-IV and its functional response to dopamine D1 receptor modulation in the living brain: a PET study in conscious monkeys. Synapse 44 (2002) 139-145
25. Hebenstreit G.F., Fellerer K., Fichte K., Fischer G., Geyer N., Meya U., et al. Rolipram in major depressive disorder: results of a double blind comparative study with imipramine. Pharmacopsychiat 22 (1989) 156-160
26. Hemmings H.C., Nairn A., and Greengard P. Protein kinases and phosphoproteins in the nervous system. In: Martin J.B., and Barchas J.D. (Eds). Neuropeptides in neurologic and psychiatric disease (1986), Raven Press, New York 47-69
27. Imanishi T., Sawa A., Ichimaru Y., Miyashiro M., Kato S., Yamamoto T., et al. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol 321 (1997) 273-278
28. Johnston A.N.B., and Rose S.P.R. Isolation-stress induced facilitation of passive avoidance memory in the day-old chick. Behav Neurosci 112 (1998) 1-8
29. Kabai P., Stewart M.G., Tarcali J., and Csillag A. Inhibiting effect of D1, but not D2 antagonist administered to the striatum on retention of passive avoidance in the chick. Neurobiol Learn Mem 81 (2004) 155-158
30. Kanes S.J., Tokarczyk J., Siegel S.J., Bilker W., Abel T., and Kelly M.P. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neurosci 144 1 (2007) 239-246
31. Lamprecht R. CREB: a message to remember. Cell Molecular Life Sci 55 4 (1999) 554-563
32. Liu F., and Graybiel M. Spatiotemporal dynamics of CREB phosphorylation in the developing striatum. Neuron 17 (1996) 1133-1144
33. Lynch M.A. Long-term potentiation and memory. Physiol Rev 84 (2004) 87-136
34. Moriuchi H., Nakahara T., Maruko T., Sakamoto K., and Ishii K. Relaxant effect of YM976, a novel phosphodiesterase 4 inhibitor, on bovine tracheal smooth muscles. Eur J Pharmacol 470 1-2 (2003) 57-64
35. O'Donnell J.M., and Frith S. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Beh 63 (1999) 85-192
36. Okulski P., Hess G., and Kaczmarek L. Anisomycin treatment paradigm affects duration of long-term potentiation in slices of the amygdala. Neurosci 114 1 (2002) 1-5
37. Randt C.T., Judge M.E., Bonnet K.A., and Quartermain D. Brain cyclic AMP and memory in mice. Pharmacol Biochem Beh 17 (1982) 677-680
38. Rose S.P.R. God's organism? The chick as a model system for memory studies. Learn Mem 7 1 (2000) 1-17
39. Rose S.P.R. Memory beyond the synapse. Neuron Glia Biology 1 (2004) 211-217
40. Rutten K., Lieben C., Smits L., and Blokland A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacol (Berlin) 192 2 (2007) 275-282
41. Schafe G.E., and LeDoux J.E. Memory consolidation of auditory Pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. J Neurosci 20 (2000) 1-5
42. Schneider H.H. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem Pharmacol 33 (1984) 1690-1693
43. Serrano P.A., Beniston D.C., Oxonian M.G., Rodriguez W.A., Rosenzweig M.R., and Bennett E.L. Differential effects of protein kinase inhibitors and activators on memory formation in the 2 day-old chick. Behav Neural Biol 61 (1994) 60-72
44. Stewart M.G., Kabai P., Harrison E., Steele R.J., Kossut M., and Gierdalsko M. The involvement of dopamine in the striatum in the passive avoidance training in the chick. Neurosci 70 (1996) 7-14
45. Zhang H.T., and O'Donnell J.M. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacol 150 3 (2000) 311-316
46. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L et al. 2007. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropharmacol 2008; 33(7):1611-162.
47. Zhao W.Q., Polya G.M., Wang B.H., Gibbs M.E., Sedman G.L., and Ng K.T. Inhibitors of cAMP-dependent protein kinase impair long-term memory formation in day-old chicks. Neurobiol Learn Mem 64 (1995) 106-118